Patents by Inventor Nicole Casadevall

Nicole Casadevall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Identification of a JAK2 Mutation in Polycythemia Vera
    Publication number: 20220042016
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: September 29, 2021
    Publication date: February 10, 2022
    Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUD
    Inventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
  • Identification of a JAK2 mutation in polycythemia vera
    Patent number: 11162100
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 2, 2021
    Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUD
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a JAK2 Mutation in Polycythemia Vera
    Publication number: 20200140863
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: January 6, 2020
    Publication date: May 7, 2020
    Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUD
    Inventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
  • Identification of a JAK2 mutation in Polycythemia Vera
    Patent number: 10563200
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: February 18, 2020
    Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES, UNIVERSITE PARIS—SUD
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a JAK2 Mutation in Polycythemia Vera
    Publication number: 20190323007
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: May 29, 2019
    Publication date: October 24, 2019
    Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Rescherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris-Sud
    Inventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
  • Identification of a JAK2 mutation in polycythemia vera
    Patent number: 10364430
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: July 30, 2019
    Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUD
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
  • IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA
    Publication number: 20150051263
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: January 27, 2014
    Publication date: February 19, 2015
    Inventors: William VAINCHENKER, Valerie UGO, Chloe JAMES, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
  • Identification of a JAK2 mutation involved in vaquez polyglobulia
    Patent number: 8852931
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: October 7, 2014
    Assignees: Assitance Publique—Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Gustave-Roussy, Universite de Versailles—St Quentin en Yvelines, Universite Paris-Sud
    Inventors: William Vainchenker, Valérie Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
  • IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA
    Publication number: 20140249204
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: January 27, 2014
    Publication date: September 4, 2014
    Applicants: Institut Gustave-Roussy, Institut National De La Sante Et De La Rechereche Scientifique (Inserm), Universite Paris-Sud, Universite De Versailles - St Quentin En Yvelines, Assistance Publique-Hopitaux De Paris
    Inventors: William Vainchenker, Valeria Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a JAK2 mutation in polycythemia vera
    Patent number: 8637235
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: January 28, 2014
    Assignees: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite de Versailles—St Quentin en Yvelines, Universite Paris—SUD
    Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a JAK2 mutation involved in vaquez polyglobulia
    Patent number: 8466338
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: June 18, 2013
    Assignees: Assistance Publique-Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave-Roussy, Universite de Versailles-St Quentin en Yvelines, Universite Paris-Sud
    Inventors: William Vainchenker, Valérie Ugo, James Chloé, Jean-Pierre Le Couedic, Nicole Casadevall
  • IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA
    Publication number: 20120066776
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: August 19, 2011
    Publication date: March 15, 2012
    Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a JAK2 mutation involved in Vaquez Polyglobulia
    Patent number: 7781199
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group, and to the identification of specific inhibitors and siRNA.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: August 24, 2010
    Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
  • IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA
    Publication number: 20090162849
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: September 19, 2008
    Publication date: June 25, 2009
    Inventors: William VAINCHENKER, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a JAK2 mutation in Polycythemia Vera
    Patent number: 7429456
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: September 30, 2008
    Assignee: IPSOGEN
    Inventors: William Vainchenker, Valeria Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
  • IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA
    Publication number: 20080076135
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: November 2, 2007
    Publication date: March 27, 2008
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
  • Identification of a jak2 mutation in polycythemia vera
    Publication number: 20060288432
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group, and to the identification of specific inhibitors and siRNA.
    Type: Application
    Filed: October 26, 2005
    Publication date: December 21, 2006
    Inventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall